Literature DB >> 26401475

Imaging of Resected Nonfunctioning Pituitary Adenomas: The Cost of Surveillance.

Heather M Kistka1, Rebecca A Kasl2, Arash Nayeri2, Andrea L Utz3, Kyle D Weaver1, Lola B Chambless1.   

Abstract

Objectives To determine the cost of annual magnetic resonance imaging (MRI) surveillance after resection of nonfunctioning pituitary adenomas (NFPAs) and its effectiveness in reducing visual compromise due to tumor recurrence. Design Retrospective case series. Setting Vanderbilt University Medical Center (2003-2011). Participants A total of 120 patients underwent primary transsphenoidal resection and surveillance of NFPAs between 2003 and 2011. Main Outcome Measures Time from initial surgery to most recent imaging or progression. Surveillance MRI costs according to Centers for Medicare and Medicaid database and visual field deficits. Results Patients received 382 surveillance scans at a total cost of $218,477.30. The median follow-up was 47 months (interquartile range [IQR]: 26-76), and the median interval between scans was 357 days (IQR: 225-434). Overall, 50 scans (13%) revealed tumor growth. The cost per scan revealing growth was $4,369.55. The cost to identify 19 patients (16%) with clinically significant growth was $11,498.80 per patient. A total of 5 of 19 patients (26%) experienced new visual deficits prior to intervention. Patients with visual decline tended to have longer scan intervals than those with preserved vision (mean: 239 versus 794 days; p = 0.0584). No patient with annual surveillance imaging experienced visual decline. Conclusions Annual MRI scans are a sensitive and cost-conscious method to identify NFPA recurrence prior to visual decline.

Entities:  

Keywords:  MRI; cost; follow-up; management; pituitary adenoma

Year:  2015        PMID: 26401475      PMCID: PMC4569503          DOI: 10.1055/s-0035-1549307

Source DB:  PubMed          Journal:  J Neurol Surg B Skull Base        ISSN: 2193-634X


  31 in total

Review 1.  The role of outcomes data for assessing the expertise of a pituitary surgeon.

Authors:  Kiarash Shahlaie; Nancy McLaughlin; Amin B Kassam; Daniel F Kelly
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2010-08       Impact factor: 3.243

Review 2.  Natural history of postoperative nonfunctioning pituitary adenomas: a systematic review and meta-analysis.

Authors:  Yong Chen; Cheng De Wang; Zhi Peng Su; Yun Xiang Chen; Lin Cai; Qi Chuan Zhuge; Zhe Bao Wu
Journal:  Neuroendocrinology       Date:  2012-08-28       Impact factor: 4.914

3.  Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

Authors:  Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde
Journal:  J Biomed Inform       Date:  2008-09-30       Impact factor: 6.317

Review 4.  Predictive markers of pituitary adenoma behavior.

Authors:  George Kontogeorgos
Journal:  Neuroendocrinology       Date:  2006-10-13       Impact factor: 4.914

5.  Quality of life is decreased after treatment for nonfunctioning pituitary macroadenoma.

Authors:  O M Dekkers; A A van der Klaauw; A M Pereira; N R Biermasz; P J Honkoop; F Roelfsema; J W A Smit; J A Romijn
Journal:  J Clin Endocrinol Metab       Date:  2006-06-20       Impact factor: 5.958

6.  Nonfunctioning pituitary adenoma: incidence, causes of death and quality of life in relation to pituitary function.

Authors:  Eigil Husted Nielsen; Jörgen Lindholm; Peter Laurberg; Per Bjerre; Jens Sandahl Christiansen; Claus Hagen; Svend Juul; Jesper Jørgensen; Anders Kruse; Kirstine Stochholm
Journal:  Pituitary       Date:  2007-03-14       Impact factor: 4.107

7.  Patient characteristics affecting attendance at general outpatient clinics.

Authors:  R J McClure; S J Newell; S Edwards
Journal:  Arch Dis Child       Date:  1996-02       Impact factor: 3.791

8.  Cell proliferation parameters and apoptosis indices in pituitary macroadenomas.

Authors:  R M Ruggeri; G Costa; A Simone; A Campennì; A Sindoni; A Ieni; V Cavallari; F Trimarchi; L Curtò
Journal:  J Endocrinol Invest       Date:  2011-09-06       Impact factor: 4.256

9.  Magnetic resonance imaging criteria to predict complete excision of parasellar pituitary macroadenoma on postoperative imaging.

Authors:  S E J Connor; F Wilson; K Hogarth
Journal:  J Neurol Surg B Skull Base       Date:  2013-08-21

Review 10.  Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira
Journal:  Pituitary       Date:  2012-03       Impact factor: 4.107

View more
  2 in total

Review 1.  Non-functioning pituitary adenomas: growth and aggressiveness.

Authors:  Kristin Astrid Øystese; Johan Arild Evang; Jens Bollerslev
Journal:  Endocrine       Date:  2016-04-11       Impact factor: 3.633

2.  Phosphorylation of β-catenin at Serine552 correlates with invasion and recurrence of non-functioning pituitary neuroendocrine tumours.

Authors:  Pinaki Dutta; Carles Gaston-Massuet; Ashutosh Rai; Soujanya D Yelamanchi; Bishan D Radotra; Sunil K Gupta; Kanchan K Mukherjee; Manjul Tripathi; Rajesh Chhabra; Chirag K Ahuja; Narendra Kumar; Akhilesh Pandey; Márta Korbonits
Journal:  Acta Neuropathol Commun       Date:  2022-09-16       Impact factor: 7.578

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.